The U.S. Food and Drug Administration has cleared the Accure Laser System for the long-term treatment of mild to severe inflammatory acne vulgaris.
The Accure Laser System uses a 1726 nm laser to selectively target overactive sebaceous glands and reduce sebum production in all skin types. The full treatment consists of a series of four treatment sessions, each completed one month apart. The laser uses a sophisticated thermal imaging camera to constantly assess the skin’s temperature, in combination with a powerful cooling system for a “treat-to-temperature” approach.
Accure Acne recently completed a limited commercial release earlier this year in the United States,. Since then, Accure has expanded the availability of the Accure Laser System in multiple regions, with first adopters in the Middle East, Europe, The Caribbean, and Asia Pacific.
“After many years of rigorous technical, scientific, and clinical development, The Accure Laser has delivered yet another milestone achievement-the ability to provide a significant, sustained, and durable drug-free alternative for acne patients and their providers,” says Christopher Carlton, Accure Acne, Inc.’s Co-Founder, Chairman of the Board and Chief Executive Officer, in a news release. “This is the vision of Accure Acne and our North Star. Having achieved this, we remain committed to further expanding the use of the Accure Laser and welcome clinicians around the world to partner with us.”
